QUÉBEC CITY, Oct. 27, 2016 /PRNewswire/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Company"), an innovator in sterilization technology formedical devices in healthcare settings, has been invited to present at Canaccord Genuity Medical Technologies & Diagnostics Forum being held on November 17, 2016 at the Westin Grand Central in New
TSO3 President and CEO R.M. (Ric) Rumble is scheduled to present on Thursday, November 17, 2016 at 3:40 p.m. EST. He will be joined by the Company's CFO Glen Kayll for one-on-one meetings held throughout the day.
Management will discuss the Company's business, and commercial rollout of its STERIZONE® VP4 Sterilizer, as well as recently received U.S. clearance for extended claims for this medical device sterilizer.
The presentation will be webcast live at http://wsw.com/webcast/canaccord24/tos, which will be available for replay in the Investors section at www.tso3.com.
For more information about the conference or to schedule a one-on-one meeting with TSO3 management, please contact your Canaccord representative.
Founded in 1998, TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
TSO3 recently announced that it had received U.S. clearance for extended claims relating to the terminal sterilization of multi-channel flexible endoscopes. The FDA clearance of additional claims represents an entirely new level of patient protection against ineffective device reprocessing resulting from the use of less robust systems like high-level disinfection, particularly for video colonoscopes and gastroscopes.
For more information about TSO3, visit the Company's web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO3's sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, the ability of the Company to obtain the required regulatory clearance to market its products on a worldwide basis;general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
SOURCE TSO3 Inc.
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All